- Home
- RHI vs ACLX Comparison
RHI vs ACLX Comparison
Compare RHI & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHI
- ACLX
- Stock Information
- Founded
- RHI 1948
- ACLX 2015
- Country
- RHI United States
- ACLX United States
- Employees
- RHI N/A
- ACLX N/A
- Industry
- RHI Professional Services
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- RHI Consumer Discretionary
- ACLX Health Care
- Exchange
- RHI Nasdaq
- ACLX Nasdaq
- Market Cap
- RHI 3.3B
- ACLX 4.4B
- IPO Year
- RHI N/A
- ACLX 2022
- Fundamental
- Price
- RHI $27.80
- ACLX $90.80
- Analyst Decision
- RHI Sell
- ACLX Strong Buy
- Analyst Count
- RHI 7
- ACLX 9
- Target Price
- RHI $40.00
- ACLX $117.78
- AVG Volume (30 Days)
- RHI 3.0M
- ACLX 381.7K
- Earning Date
- RHI 10-22-2025
- ACLX 11-05-2025
- Dividend Yield
- RHI 8.53%
- ACLX N/A
- EPS Growth
- RHI N/A
- ACLX N/A
- EPS
- RHI 1.54
- ACLX N/A
- Revenue
- RHI $5,458,499,000.00
- ACLX $35,898,000.00
- Revenue This Year
- RHI N/A
- ACLX N/A
- Revenue Next Year
- RHI $0.90
- ACLX $220.95
- P/E Ratio
- RHI $17.95
- ACLX N/A
- Revenue Growth
- RHI N/A
- ACLX N/A
- 52 Week Low
- RHI $25.22
- ACLX $47.86
- 52 Week High
- RHI $78.41
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- RHI 41.99
- ACLX 60.10
- Support Level
- RHI $25.38
- ACLX $85.00
- Resistance Level
- RHI $26.29
- ACLX $90.30
- Average True Range (ATR)
- RHI 1.10
- ACLX 3.87
- MACD
- RHI 0.23
- ACLX -0.04
- Stochastic Oscillator
- RHI 55.92
- ACLX 81.59
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.